Over the past three years, the FDA has approved six new hemophilia treatments, including three gene therapies. Now, Sanofi’s Qfitlia (fitusiran) enters the competitive hemophilia therapeutics market, distinguishing itself as the only therapy approved for all types of hemophilia. Unlike most existing treatments, Qfitlia is indicated for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients (12 years and older) for both hemophilia A and B and is effective regardless of inhibitor status—a key advantage for patients who develop factor VIII or factor IX inhibitors, which can reduce the effectiveness of standard clotting factor replacem...
